School of Pharmaceutical Sciences
藥物科學院
以藥物科學為基礎,培養具生技醫藥研發、臨床專業服務、法規行政科學之學生,成為與國際接軌的藥學人才。
Read more

藥科院組織架構圖

藥物科學院院教評會委員名單

組織成員

康照洲教授
Kang, Jaw-Jou
藥物科學院院長 2016年迄今
食品安全及健康風險評估研究所所長 2016年迄今
02-28267000 #7300
Office:行政大樓301室
美國加州大學聖地牙哥分校|化學博士1983-1989
中華民國國立臺灣大學|藥學學士1975-1979
  • 專長
    毒性測試、藥物管理及安全、食品管理及安全、安全性(風險)評估
  • 現職
    • 國立陽明大學藥物科學院院長
    • 國立臺灣大學毒理學研究所教授
    • 中華民國毒物學會理事長
  • 經歷
    • 行政院食品安全辦公室主任2015年2月至2016年9月
    • 行政院衛生署食品藥物管理局局長2010年1月至2013年7月
    • 行政院衛生署藥物食品檢驗局局長2009年10月至2009年12月
    • 行政院衛生署藥政處處長 2009年8月至2009年12月
    • 國立台灣大學醫學院藥物研究中心主任 2007年8月至2009年7月
    • 國立台灣大學毒理學研究所副教授 1991年8月至1998年7月
    • 波士頓生物醫學研究所博士後研究 1989年6月至1991年7月
  • 論文
    1. Motorcycle exhaust particles up-regulate expression of vascular adhesion molecule-1 and intercellular adhesion molecule-1 in human umbilical vein endothelial cells. Lee, .CC., Huang, S.H., Yang, Y.T., Cheng, Y.W., Li, C.H. and Kang, J.J.* Toxicology in vitro (26):552-560, 2012.
    2. Organ biodistribution, clearance, and genotoxicity of orally administered zinc oxide nanoparticles in mice. Li, C.H., She, C.C., Cheng, Y.W., Huang, S.H., Wu, C.C., Kao, C.C., Liao, J.W. and Kang, J.J.* Nanotoxicology (6):746-756, 2012
    3. Zinc oxide nanoparticles induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed-lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells. Li, C.H., Liao, P.L., Shyu, M.K., Liu, C.W., Kao, C.C., Huang, S.H., Cheng, Y.W. and Kang, J.J.* Toxicological Sciences (126):162-172, 2012.
    4. Crisis management turns Taiwan's plasticizer nightmare into progressive policy. Kang, J.J., Chu, S.F., Wu, Z.Z., Chou, S.W., Tsai, S.J. and Chiu, W.T. J Formos Med Assoc. 111(8):409-11, 2012.
    5. Antiallergic asthma properties of brazilin through inhibition of TH2 responses in T cells and in a murine model of asthma. Lee, C.C., Wang, C.N., Kang, J.J., Liao, J.W., Chiang, B.L., Chen, H.C., Hu, C.M., Lin, C.D., Huang, S.H., and Lai Y.T. J Agric Food Chem. 19;60(37):9405-14, 2012.
    6. Metabolism of (2S)-pterosin A: identification of the phase I and phase II metabolites in rat urine. Lee, Y.P., Hsu, F.L., Kang, J.J., Chen, C.K. and Lee, S.S. Drug Metab Dispos. 40 (8):1566-74, Aug, 2012.
    7. Metabolomic analysis of complex chinese remedies: examples of induced nephrotoxicity in the mouse from a series of remedies containing aristolochic Acid. Tsai DM, Kang JJ, Lee SS, Wang SY, Tsai IL, Chen GY, Liao HW, Wei-Chu L, Kuo CH, Tseng YJ., Evid Based Complement Alternat Med. , 2013:263757
    8. Evaluation of acute, 13-week subchronic toxicity and genotoxicity of the powdered root of Tongkat Ali (Eurycoma longifolia Jack). Li, C.H., Liao, J.W., Liao, P.L., Huang, W.K., Tse, L.S., Lin, C.H., Kang, J.J.* and Cheng, Y.W.* Evidence-Based Complementary and Alternative Medicine., 2013
    9. Minocycline accelerates hypoxia-inducible factor-1 alpha degradation and inhibits. Li, C.H., Liao, P.L., Yang, Y.T., Huang, S.H., Lin, C.H., Cheng, Y.W. and Kang, J.J.* Archives of Toxicology, 88(3):659-671, 2014
    10. Metabolites of antroquinonol found in rat urine following oral administration, Chien-Kuang Chen, Jaw-Jou Kang, Wu-Che Wen, Hui-Fen Chiang, and Shoei-Sheng Lee, Journal of Natural Products, 25;77(4):1061-4, 2014.
    11. Snail regulates Nanog status during the epithelial-mesenchymal transition via the Smad1/Akt/GSK3β signaling pathway in non-small-cell lung cancer. Liu CW, Li CH, Peng YJ, Cheng YW, Chen HW, Liao PL, Kang JJ*, Yeng MH*., Oncotarget, 5(11): 3880–3894, 2014.
    12. Zinc oxide nanoparticles impair bacterial clearance by macrophages., Lin CD, Kou YY, Liao CY, Li CH, Huang SP, Cheng YW, Liao WC, Chen HX, Wu PL, Kang JJ, Lee CC, Lai CH., Nanomedicine (Lond), 9(9):1327-39, 2014.
    13. The evolution and challenges for the international harmonization of the regulation of pharmaceutical excipients in Taiwan. Lin-Chau Chang, Jaw-Jou Kang, Churn-Shiouh Gau, Regulatory Toxicology and Pharmacology, 73, 947-952, 2015.
    14. Gold nanoparticles increase endothelial paracellular permeability by altering components of endothelial tight junctions, and increase blood-brain barrier permeability in mice, Li CH, Shyu MK, Jhan C, Cheng YW, Tsai CH, Liu CW, Lee CC, Chen RM, Kang JJ*. Toxicological Sciences, 148(1):192-203, 2015.
    15. NcoA2-dependent inhibition of HIF-1α activation is regulated via AhR., Chi-Hao Tsai, Ching-Hao Li, Po-Lin Liao, Yu-Wen Cheng, Cheng-Hui Lin, Shih-Hsuan Huang, and Jaw-Jou Kang*, Toxicological Sciences, 148(2):517-30, 2015.
    16. Development of the risk-based, phased-in approach for the international harmonization of the regulation of container closure systems for drugs in Taiwan., Lin-Chau Chang, Jaw-Jou Kang, Churn-Shiouh Gau, Regulatory Toxicology and Pharmacology, 77:252-256, 2016.
    17. Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4, Chen-Chen Lee, Wen-Hao Yang, Ching-Hao Li, Yu-Wen Cheng, Chi-Hao Tsai, Jaw-Jou Kang*, CANCER LETTERS, 2016 Jul, 376(2):211-217, SCI.
蕭崇瑋教授
Chung-Wai Shiau
生物藥學研究所所長
02-28267000 #7930
Ph.D.The Ohio State University, USA
中興大學|化學系
  • 研究領域
    • 1. New drugs design and synthesis.
    • 2. Pharmacology of novel agents for anticancer research
  • 現職
    • Faculty member, Institute of Biopharmaceutical Sciences, National Yang-Ming University2008年迄今
    • Dean, School of Pharmaceutical Sciences, National Yang-Ming University 2017年8月迄今
  • 經歷
    • Professor, Institute of Biopharmaceutical Sciences, National Yang-Ming University.(陽明大學生藥所)2015年迄今
    • Associate professor, Institute of Biopharmaceutical Sciences, National YangMing University.2012-2015
    • Assistant professor, Institute of Biopharmaceutical Sciences, National YangMing University.2008-2012
    • Postdoctoral Fellow, Apoptosis and Cell Death Program, The Burnham Institute for Medical Research.2005-2008
  • 出版
    1. Huang CY, Tai WT, Wu SY, Shih CT, Chen MH, Tsai MH, Kuo CW, Shiau CW, Hung MH,Chen KF. Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling. Int J Radiat Oncol Biol Phys. 2016; in press
    2. Tai WT, Hung MH, Chu PY, Chen YL, Chen LJ, Tsai MH, Chen MH, Shiau CW, Boo YP, Chen KF. SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma. Oncotarget. 2016, in press
    3. Hung MH, Chen YL, Chu PY, Shih CT, Yu HC, Tai WT, Shiau CW, Chen KF. Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential. Oncogene. 2016; in press
    4. Tai WT, Chen YL, Chu PY, Chen LJ, Hung MH, Shiau CW, Huang JW, Tsai MH, Chen KF. Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma. Hepatology. 2016; in press
    5. Liu CY, Hu MH, Hsu CJ, Huang CT, Wang DS, Tsai WC, Chen YT, Lee CH, Chu PY, Hsu CC, Chen MH, Shiau CW, Tseng LM, Chen KF. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Oncotarget, 2016; in press
    6. Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Cancer letters. 2016; 371, 205-13.
    7. Chang HC, Huang YT, Chen CS, Chen YW, Huang YT, Su JC, Teng LJ, Shiau CW, Chiu HC. In vitro and in vivo activity of a novel sorafenib derivative SC5005 against MRSA. J Antimicrob Chemother. 2016; 71, 449-59
    8. Hung MH, Wang CY, Chen YL, Chu PY, Hsiao YJ, Tai WT, Chao TT, Yu HC, Shiau CW*, Chen KF. SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A. Oncotarget. 2016; 7, 638-55.
    9. Fan LC, Teng HW, Shiau CW, Tai WT, Hung MH, Yang SH, Jiang JK, Chen KF. Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer. NEOPLASIA. 2015; 17:687-696.
    10. Chao TT, Wang CY, Chen YL, Lai CC, Chang FY, Tsai YT, Chao CH, Shiau CW, Huang YC, Yu CJ, Chen KF. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. Oncotarget, 2015; 6, 2164-79.
    11. Wang SH, Yeh SH, Shiau CW, Chen KF, Lin WH, Tsai TF, Teng YC, Chen DS, Chen PJ. Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1. JNCI J Natl Cancer Inst, 2015; 107: djv190.
    12. Su TH, Shiau CW, Jao P, Liu CH, Liu CJ, Tai WT, Jeng YM, Yang HC, Tseng TC, Huang HP,Cheng HR, Chen PJ, Chen KF, Kao JH, Chen DS. Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Proc Natl Acad Sci U S A. 2015; 112, 7243-48.
    13. Fan LC, Shiau CW, Tai WT, Hung MH, Chu PY, Hsieh FS, Lin H, Yu HC, Chen KF. SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma. Oncogene.2015; 34:5252-5263.
    14. Su JC, Chang, JH, Huang JW, Chen P, Chen KF, Tseng PH, Shiau CW*. Copper–obatoclax derivative complexes mediate DNA cleavage and exhibit anti-cancer effects in hepatocellular carcinoma. Chemico-biological interaction. 2015; 228:108-113.
    15. Hung MH, Tai WT, Shiau CW, Chen KF. Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy. World J Gastroenterol. 2014; 20:15269-15274.
    16. Su JC, Chiang HC, Tseng PH, Tai WT, Hsu CY, Li YS, Huang JW, Ko CH, Lin MW, Chu PY, Liu CY, Chen KF, Shiau CW*. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. Carcinogenesis. 2014;35:2807-14
    17. Tai WT, Chu PY, Shiau CW, Chen YL, Li YS, Hung MH, Chen LJ, Chen PL, Su JC, Lin PY, Yu HC, Chen KF. STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma. Clin Cancer Res. 2014;20:5768-76.
    18. Liu CY, Hung MH, Wang DS, Chu PY, Su JC, Teng TH, Huang CT, Chao TT, Wang CY, Shiau CW, Tseng LM, Chen KF. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A dependent phospho-Akt inactivation in estrogen-receptor negative human breast cancer cells. Breast Cancer Res. 2014;16:431
    19. Chao TT, Wang CY, Lai CC, Chen YL, Tsai YT, Chen PT, Lin HI, Huang YC, Shiau CW*, Yu CJ, Chen KF. TD-19, an erlotinib derivative, induces EGFR wild-type NSCLC apoptosis through CIP2A-mediated pathway. J Pharmacol Exp Ther. 2014; 351:352-8
    20. Yu HC, Hung MH, Chen YL, Chu PY, Wang CY, Chao TT, Liu CY, Shiau CW*, Chen KF*. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death and Disease. 2014; 31: e1359.
    21. Fan LC, Teng HW, Shiau CW, Lin H, Hung MH, Huang JW, Tai WT, Yu HC, Chen KF. SHP-1 is a target of regorafenib in colorectal cancer. Oncotarget. 2014; 30:6243-51
    22. Su JC, Tseng PH, Hsu CY, Tai WT, Huang JW, Ko CH, Lin MW, Liu CY, Chen KF, Shiau CW*. RFX1–dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. 2014. Oncotarget. 2014; 15:4909-19.
    23. Liu CY, Su JC, Ni MH, Tseng LM, Chu PY, Wang DS, Tai WT, Kao YP, Hung MH, Shiau CW*, Chen KF. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells. Breast Cancer Res Treat. 2014;146:71-84.
    24. Wang CY, Chao TT, Chang FY, Chen YL, Chen YT, Lin HI, Huang, YC, Shiau CW, Yu CJ, Chen KF. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells with no EGFR mutation. Lung cancer. 2014;85:152-60
    25. Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Liu CY, Chen KF, Shiau CW*. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. Neoplasia. 2014; 16:595-605.
    26. Huang CY, Tai WT, Hsieh CY, Hsu WM, Lai YJ, Chen LJ, Shiau CW*, Chen KF. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3. Cancer Lett. 2014; 28:136-43.
    27. Tai WT, Shiau CW, Li YS, Chang CW, Huang JW, Hsueh TT, Chen KF. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity. J Hepatol. 2014;61:89-97.
    28. CY Wang, Chao TT, Tai WT, Chang FY, Su WP, Chen YL, Chen PT, Weng CY, Yuan A, Shiau CW, Yu CJ, Chen KF. Signal Transducer and Activator of Transcription 3 as Molecular Therapy for Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2014; 9:488-96.
    29. Tai WT, Shiau CW, Chen PJ, Chu P-Y, Huang HP, Liu CY, Huang JW, Cheng AL, Chen KF. Discovery of novel SHP-1 agonists from sorafenib for the treatment of HCC. Hepatology. 2014;59:190-201.
    30. Tai WT, Shiau CW, Li YS, Chen YL, Chu PY, Huang JW, Hsu CY, Hsu YC, Chen PJ, Chen KF. SC-60, a dimer-based sorafenib derivative, shows a better anti-HCC effect than sorafenib in a preclinical HCC model. Mol Cancer Ther. 2014; 13:27-36.
    31. Hou DR, Huang AC, Shiau CW, Wang CY, Yu HC, Chen KF. Bortezomib Congeners Induce Apoptosis of Hepatocellular Carcinoma via CIP2A Inhibition. Molecules 2013; 18:15398-15411.
    32. Liu CY, Tseng LM, Su, JC, Chang, KC, Chu, PY, Tai WT, Shiau CW*, Chen KF*. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 2013. 15: R68.
    33. Yu HC, Lin CS, Tai WT, Liu CY, Shiau CW, Chen KF. Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation. J Biol Chem. 2013; 288: 18249-59.
    34. Hunag CY, Lin CS, Tai WT, Hsieh CY, Shiau CW, Cheng AL, Chen KF. Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3. Int J Radiat Oncol Biol Phys. 2013;86: 456-462.
    35. Yu HC, Hou DR, Liu CY, Lin CS, Shiau CW, Cheng AL, Chen KF. Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. PLoS One. 2013; 8:e55705
    36. Tai WT, Shiau CW, Chen HL, Liu CY, Lin SL, Cheng AL, Chen PJ, Chen KF.Mcl-1 dependent activation of beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death and Disease. 2013; 4: e485
    37. Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL, Chen KF. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem Pharmacol. 2013;85:356-66.
    38. Liu CY, Shiau CW*, Ko, HY, Huang HP, Chen MH, Tzeng CH, Chen KF*. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in acute leukemia cells.Haematologica. 2013; 98:729-38.
    39. Chen KF*, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-DR5 antibody. Br. J. Pharmacol. 2013;168: 658-672
    40. Wang CT, Lin CS, Shiau CW, Chu PY, Hsiao CC, Chiang YL, Tai WT, Chen KF. SC-1, a Sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells. J. Orthopaedic Res.2013; 31: 335-42.
    41. Su JC, Chen KF, Chen WL, Liu CY, Huang JW, Tai WT, Chen PJ, Kim I, Shiau CW*. Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists. Eur J Med Chem. 2012; 56:127-33.
    42. Chen KF, Tai WT, Hsu CY, Huang JW, Liu CY, Chen PJ, Kim I, Shiau CW*. Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. Eur J Med Chem. 2012; 55:220-27.
    43. Chen KF, Pao KC, Su JC, Chou YC, Liu CY, Chen HJ, Huang JW, Kim I, Shiau, CW*. Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity.Bioorg. Med. Chem. 2012; 20:6144-53.
    44. Chen KF, Lin JP, Shiau CW, Tai WT, Liu CY, Yu HC, Chen PJ, Cheng AL. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochem Pharmacol. 2012; 84:268-77. (Co-first author)
    45. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res. 2012; 14: R68.
    46. Chen KF, Su JC, Liu CY, Huang JW, Chen KC, Chen WL, Tai WT, Shiau CW*. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation. Cancer Lett. 2012; 321:27-35.
    47. Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ, Chen KF. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Mol Cancer Ther. 2012; 11:452-63.
    48. Shih KC, Shiau CW, Chen TS, Ko CH, Lin CL, Lin CY, Hwang CS, Tang CY, Chen WR, Huang JW. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.Bioorg Med Chem Lett. 2011; 21:4490-7.
    49. Chen KF, Tai WT, Huang JW, Hsu CY, Chen WL, Cheng AL, Chen PJ, Shiau CW*. Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. Eur J Med Chem.2011; 46:2845-51.
    50. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol. 2011; 55:1041-8.
  • 補助
    計畫
  • 得獎
    • 國家新創獎2014
    • California Breast Cancer Research Program Postdoctoral Fellowship.2006
    • Albert H. Soloway Graduate Student Award in Pharmacy and Cancer Research.2004
    • Scholarship offered by Ministry of Education of Taiwan.1997
  • 專利
    • Small molecule Bcl-xL/Bcl-2 binding inhibitors. USA. 20060252801. 2006.
    • Agonists of SRC homology-2 containing protein tyrosine phoshpastase-1 and treatment methods using the same. USA. Provisional. 2011.
    • Agonists of SRC homology-2 containing protein tyrosine phoshpastase-1 and treatment methods using the same. 2015 (USA, Canada, Taiwan, New Zealand, China)
    • Aryl Amine Substituted Pyrimidine and Quinazoline and Their Use as Anticancer Drugs. 2012
林滿玉教授
Lin, Anya Maan-Yuh
藥學院|主任 2016年迄今
(02)28267000#7983
(02)28712121#2688
myalin@ym.edu.tw
myalin@vghtpe.gov.tw
美國科羅拉多州州立大學|藥理學博士1989-1992
中華民國國立臺灣大學|藥理學碩士1982-1984
中華民國國立臺灣大學|藥學士 1978-1982
  • 專長
    神經藥理、神經再生、轉譯醫學研究
  • 現職
    • 國立陽明大學|藥學院|主任2016年迄今
    • 國立陽明大學|藥理學研究所|專任教授 2008年8月迄今
    • 臺北市石牌榮民總醫院|教學研究部|合聘研究員 2005年8月迄今
  • 經歷
    • 國立陽明大學|藥學院籌備處|主任2015年8月至2016年7月
    • 國立陽明大學|藥理學研究所|所長2008年8月至2014年
    • 國立陽明大學|生理學研究所|專任教授 2005年8月至2008年7月
    • 臺北市石牌榮民總醫院|教學研究部|專任研究員 2004年至2005年7月
    • 國立陽明大學|生理學研究所|兼任副教授 1998年至2005年2月
    • 臺北市石牌榮民總醫院|教學研究部|專任副研究員 1996年至2004年
    • 中央研究院|生物醫學科學研究所|博士後研究員 1993年10月至1996年10月
    • 美國國家衛生研究院|客座博士後研究員 1992年8月至1993年9月
  • 論文
    1. Teng YC, Jeng CJ, Huang HJ, Lin AMY*. Role of autophagy in arsenite-induced neurotoxicity: the involvement of α-synuclein. Toxicol Lett. 2015 Mar 18;233(3):239-45.
    2. Tang MC, Wu MY, Hwang MH, Chang YT, Huang HJ, Lin AMY*, Yang JCH. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells. PLoS One. 2015 Mar 25; 10(3):e0119135.
    3. Teng YC, Tai YI, Huang HJ, Lin AMY.* Melatonin ameliorates arsenite-induced neurotoxicity: involvement of autophagy and mitochondria. Mol Neurobiol. 2015 Oct;52(2):1015-22
    4. Hung KC, Huang HJ, Lin MW, Lei YP, Lin AMY.* Roles of autophagy in MPP+-induced neurotoxicity in vivo: the involvement of mitochondria and α-synuclein aggregation. PLoS One. 2014 Mar 19;9(3):e91074.
    5. Teng YC, Tai YI, Lee YH, Lin AMY.* Role of HO-1 in the arsenite-induced neurotoxicity in primary cultured cortical neurons. Mol Neurobiol. 2013 Oct;48(2):281-7.
    6. Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin AMY,* Yang JC.MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol. 2013 Feb;7(1):112-20.
    7. Lee YC, Lee LM, Yang CH, Lin AMY*, Huang YC, Hsu CC, Chen MS, Chi CW, Yin PH, Kuo CD, Liao JF, Lee HC. Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells. Oncol Rep. 2013 Jan;29(1):237-43.
    8. Chang CF, Huang HJ, Lee HC, Hung KC, Wu RT, Lin AMY*. Melatonin attenuates kainic acid-induced neurotoxicity in mouse hippocampus via inhibition of autophagy and α-synuclein aggregation.J Pineal Res. 2012 Apr;52(3):312-21.
    9. Lin AMY*, Wu LY, Hung KC, Huang HJ, Lei YP, Lu WC, Hwang LS. Neuroprotective effects of longan (Dimocarpus longan Lour.) flower water extract on MPP+-induced neurotoxicity in rat brain. J Agric Food Chem. 2012 Sep 12;60(36):9188-94.
    10. Lin AMY*, Ping YH, Chang GF, Wang JY, Chiu JH, Kuo CD, Chi CW. Neuroprotective effect of oral S/B remedy (Scutellaria baicalensis Georgi and Bupleurum scorzonerifolfium Willd) on iron-induced neurodegeneration in the nigrostriatal dopaminergic system of rat brain. J Ethnopharmacol. 2011 Apr 12;134(3):884-91.
    11. Lin A.M.Y., Feng S.F., Chao P.L., Yang C.H. Melatonin inhibits arsenite-induced peripheral neurotoxicity. J. Pineal. Res. 46: 64-70(2009)
    12. Fan S.F., Chao P.L., Lin A.M.Y. Arsenite induces oxidative injury in rat brain: Synergistic effect of iron. Ann. N. Y. Acad. Sci. (in press)
    13. Chao YH, P.L. Chao, Tsai MJ, Cheng HH., CGen KB., Yang DM., C.H. Yang, Lin A.M.Y. Arsenite-induced cytotoxicity in DRG explants. Free. Radic. Biol. Med. 44: 1553-1561 (2008)
    14. Lin A.M.Y. Fang S.F., Chao P.L., Yang C.H. Melatonin attenuates arsenite-induced apoptosis in rat brain: Involvement of mitochondrial and ER pathways and aggregation of a-synuclein. J. Pineal. Res. 43(2): 163-171 (2007)
    15. Lin A.M.Y., Chao P.L., Fang S.F., Chi C.W., Yang C.H. Endoplasmic reticulum stress is involved in arsenite-induced oxidative injury in rat brain. Toxicol. Appl Pharmacol. 224: 138-146 (2007)
    16. Chao P.L., Fan S.F., Chou Y.H., Lin A.M.Y. N-acetylcysteine attenuates arsenite-induced oxidative injury in DRG explants. Ann. N.Y. Acad. Sci. 1122: 276-288. (2007)
葉依瑄
Yeh, Yi-Shuan
藥物科學院|專案組員
02-28267000 #2002